Targeted Oncology5h
Pembrolizumab/Chemo Continues to Impress in NSCLC With 5-Year Updates
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...
Texas parole board denies clemency for man in ‘shaken baby' death
The Texas Board of Paroles and Pardons has denied recommending clemency for Robert Roberson III one day before his scheduled ...
Targeted Oncology2d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Lung cancer spit test fast-tracks a San Antonio biotech company for growth
More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...
360dx7d
Stratipath Seeks to Ramp up Adoption of AI-Based Breast Cancer Test
The company continues to build validation data and believes its lower cost proposition can help it gain leverage in the European market where molecular tests are not reimbursed.
verywellhealth15d
How Chronic Obstructive Pulmonary Disease (COPD) Is Treated
Chronic obstructive pulmonary disease (COPD), an irreversible form of lung disease, is treated with prescription drugs, lifestyle changes, rehabilitation therapies, and surgery in certain cases. The ...
thorax.bmj15d
Pulmonary fibrosis may begin in infancy: from childhood to adult interstitial lung disease
The lung can respond to injury with different patterns of interstitial fibrosis, including fibrosing non-specific interstitial pneumonia (NSIP), and, though rare in childhood, usual interstitial ...
eLife16d
β-glucan reprograms alveolar macrophages via neutrophil/IFNγ axis to promote lung injury
Alveolar macrophages (AMs) reside in the lower airways and play a crucial role in lung health and response to sterile inflammation and infections. AMs possess remarkable adaptability to different ...
BioPharma Dive19d
FDA, after delay, clears Regeneron and Sanofi drug for COPD
The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung condition. The decision could significantly expand use ...
Reuters21d
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The health regulator has cleared the drug's use as an add-on treatment for some adults with inadequately controlled chronic obstructive pulmonary disease (COPD), a condition that progressively ...
FiercePharma21d
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
Over the last decade, as other companies—such as AstraZeneca with IL-5 inhibitor Fasenra—struggled to advance candidates for COPD, Regeneron and Sanofi took a more “phenotype-driven approach ...
MedPage Today22d
First-Ever Biologic Approved for COPD
Opens in a new tab or window The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on ...